Cancilico Secures €2.5M Seed Round to Advance AI Oncology Diagnostics

Why It Matters

By automating complex haematology diagnostics, Cancilico can improve patient outcomes while easing the strain on scarce specialist resources, accelerating the adoption of AI in clinical labs worldwide.

Key Takeaways

• €2.5M seed round led by HTGF and regional funds.
• MyeloAID runs on existing microscopes, no hardware upgrade.
• AI model trained on malignant and healthy samples improves accuracy.
• Addresses global haematologist shortage by automating diagnostics.
• Funding targets FDA and CE‑IVDR approvals and market rollout.

Pulse Analysis

The integration of artificial intelligence into oncology diagnostics has moved from experimental labs to frontline laboratories, driven by mounting pressure to deliver faster, more reliable results. Blood cancers, in particular, demand precise interpretation of bone‑marrow smears, a task traditionally reserved for highly trained haematopathologists. With a global shortfall of specialists and increasing case complexity, hospitals are seeking scalable solutions that can maintain diagnostic quality without costly equipment upgrades. Cancilico’s recent €2.5 million seed round reflects investor confidence that AI can bridge this gap and reshape standard‑of‑care protocols.

MyeloAID, Cancilico’s flagship software, distinguishes itself by running on any conventional imaging microscope or scanner, eliminating the need for dedicated AI hardware. The platform’s neural network was trained on a curated dataset comprising thousands of malignant and healthy specimens, enabling it to differentiate subtle morphological patterns with higher speed and accuracy than manual review. Strategic collaborations with haematopathology centres and early‑stage pharma partners enrich the model’s robustness and open pathways for digital biomarker discovery. This plug‑and‑play approach lowers adoption barriers for midsize labs across Europe and beyond.

The seed financing, led by High‑Tech Gründerfonds and regional funds, earmarks resources for navigating FDA and CE‑IVDR regulatory frameworks and scaling commercial operations. Successful clearance would position MyeloAID as one of the first AI‑assisted diagnostic tools to achieve simultaneous market entry in the United States and the European Union, a rare feat in med‑tech. Beyond immediate revenue, the technology promises to accelerate therapeutic development by providing standardized, high‑throughput data for clinical trials. As AI gains regulatory acceptance, Cancilico’s model could set a benchmark for future AI‑enabled pathology solutions.

Deal Summary

Dresden-based AI diagnostics startup Cancilico announced a €2.5 million seed round led by High-Tech Gründerfonds, TGFS - Technologiegründerfonds Sachsen, GEDAD GmbH and ROI Verwaltungsgesellschaft. The funding will support the development of its MyeloAID platform for blood cancer diagnostics and help navigate regulatory pathways. The round includes a consortium of German venture funds and an investment vehicle of the Ehninger family.